CMD001

CMD001 is a preclinical protein-based therapeutic being developed by COMED Therapeutics for the treatment of pancreatic cancer. The drug is engineered to be delivered using COMED's proprietary intracellular delivery platform, which is designed to transport large molecules such as proteins, peptides, and nucleic acids across the cell membrane to reach intracellular targets. While the specific molecular target of CMD001 has not been publicly disclosed, the program represents a novel approach to pancreatic cancer by leveraging advanced delivery technology to enable protein-based modulation of disease pathways within the cytoplasm or nucleus.